This page shows the latest Genmab news and features for those working in and with pharma, biotech and healthcare.
Darzalex, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.
Janssen developed JNJ-6372 in collaboration with Genmab, which is also its collaborator on blockbuster multiple myeloma therapy Darzalex (daratumumab) and follow-up HexaBody-CD38.
lagging behind rivals in the market such as Johnson &Johnson and Genmab’s CD38 inhibitor Darzalex (daratumumab). ... Earlier this month, Sanofi claimed FDA approval for Sarclisa (isatuximab) in relapsed/refractory myeloma, while J&J and Genmab already
GSK is just the latest in a series of drugmakers to cut deals with Immatics for access to its cell therapy expertise, and it has previously partnered withRoche and Genmab.
Darzalex, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.
The drug, which was originally developed by Danish biotech Genmab, is a monoclonal antibody (mAb) that targets the CD38 protein, which is highly expressed on multiple myeloma cells.
More from news
Approximately 7 fully matching, plus 46 partially matching documents found.
Another of its partners, Horizon Therapeutics recently submitted to the FDA the Genmab-developed teprotumumab for the treatment of active thyroid eye disease. ... If approved, this would become Genmab’s third product on the market, behind Darzalex and
469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.
Exclusive global licence. 510. Genmab. Novo Nordisk. Bispecific antibody candidates outside oncology indications.
244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
Four years ago Genmab started working with Seattle Genetics' ADC technology and has now signed a new deal using a Genmab antibody. The creative aspect of this deal is that Seattle ... has retained an option to increase the Genmab royalties to double
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
In his new role, Mancini will oversee all of Genmab’s commercial, corporate development, business development and information technology functions. ... operations during this transformational stage for Genmab,”said Jan van de Winkel, chief executive
Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number
Current president and chief executive officer of Genmab, Dr van de Winkel joins the board with over 25 years’ experience in the therapeutic antibody field. ... Dr van de Winkel’s career experience has seen him serve Medarex Europe as its vice
Dr Judith Klimovsky becomes chief development officer. Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer. ... Jan van de Winkel, Genmab's chief executive, said: “We are very
at Charles River Laboratories, where he worked on clinical trial programmes for Ferring, Genmab, AstraZeneca, and Aerocrine (spending much of his time in Scandinavia).
More from appointments
Approximately 1 fully matching, plus 5 partially matching documents found.
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...